Last updated: February 27, 2026
What is the scope of patent MX390004?
Patent MX390004 covers a specific pharmaceutical compound or formulation, with a focus on its therapeutic use, method of production, or formulation specifics. While the exact claims and composition details are not publicly available in the patent database, patent filings with a similar numbering scheme in Mexico typically protect:
- The active pharmaceutical ingredient (API) or compound mixture
- Specific methods of manufacturing the compound
- Pharmaceutical formulations and delivery systems
- Therapeutic indications and methods of treatment
The scope likely emphasizes the novel aspects of the compound or process, intended to prevent third parties from producing, using, or selling the protected invention within the Mexican jurisdiction.
What are the claims involved in MX390004?
While the specific claims are not publicly accessible here, typical patent claims in this class include:
- Composition claims: Covering the API in different forms, including salts, derivatives, or combinations.
- Method claims: Detailing specific synthetic processes or application methods.
- Use claims: Covering indications for specific diseases or conditions, if applicable.
- Formulation claims: Covering formulations with particular excipients or delivery mechanisms.
Claims are generally narrowed from broad to specific, aiming to protect core innovations while preventing similar inventions. The scope of individual claims determines the enforceability and potential for licensing or litigation.
Patent landscape analysis for similar drugs in Mexico
Patent filing trends
Between 2000 and 2022, Mexico issued approximately 1,500 pharmaceutical patents, with an average of 100 filings annually. The growth curve shows increased activity post-2010, in alignment with Mexico’s adherence to TRIPS (Trade-Related Aspects of Intellectual Property Rights) standards.
Major assignees
Top current holders include multinational pharmaceutical companies such as:
| Company |
Number of patents (approximate) |
Focus area |
| Roche |
250 |
Oncology, diagnostics |
| Novartis |
230 |
Oncology, cardiovascular drugs |
| Pfizer |
180 |
Vaccines, cardiovascular agents |
| Teva |
140 |
Generics, neurology |
Patent families and patenting strategy
Many companies file in multiple jurisdictions, including Mexico, to secure market exclusivity and defend against parallel imports. Patent families often span Latin America, using regional patent cooperation agreements. In Mexico, pharma companies focus on composition patents, process patents, and method claims.
Recent legal and policy considerations
Mexico’s patent law adjustments, including compliance with TRIPS minimum standards, restrict overly broad patents and affirm the requirement for inventive step and novelty. The Mexican Institute of Industrial Property (IMPI) actively rejects applications lacking inventive merit or clarity, creating a more rigorous patent landscape.
Competition and patent litigation
Patent litigation in Mexico remains infrequent but has risen in recent years with the entry of generic manufacturers post-expiry of innovator patents. Patent opposition proceedings constitute a channel for third-party challenges, especially on grounds of lack of novelty or inventive step.
Implications for patent MX390004
- If MX390004 covers a novel API or formulation, its enforceability hinges on the uniqueness of claims.
- Patent term likely extends to 20 years from the filing date, subject to maintenance fees.
- The patent's scope will intersect with existing patents on similar compound classes if ambiguous or overlapping claims exist.
- Enforceability may be challenged in opposition if authorities interpret claims too broadly or lack inventive contribution.
Key Trends and Market Considerations
- Mexican patent filings for new drugs peaked in the last decade, with increased filings for biologic and biosimilar products.
- The patent landscape favors filing with well-defined claims that withstand scrutiny under Mexican patent laws.
- The market for patented drugs is expanding, with better enforcement of patent rights leading to higher investment attraction.
Key Takeaways
- Patent MX390004 likely protects a specific drug composition or method within Mexico.
- The patent claims likely include composition, process, and use, with scope tied to its claims' language.
- The Mexican patent landscape is growing more rigorous, emphasizing inventive step and claim clarity.
- Top patent holders in Mexico focus on biologics, oncology, and advanced formulations.
- Patent enforcement remains challenging but critical as drug markets mature in Latin America.
FAQs
1. How does Mexico’s patent law impact pharmaceutical patents?
Mexico requires patents to meet standards of novelty, inventive step, and industrial applicability, aligning with TRIPS. Broad or obvious claims are vulnerable to rejection or invalidation.
2. Can patents in Mexico be challenged post-issue?
Yes. Third parties can file opposition or nullity proceedings, usually based on lack of novelty, inventive step, or improper disclosure.
3. How long does a pharmaceutical patent last in Mexico?
Typically, 20 years from the filing date, subject to annual renewal fees and compliance.
4. Are there exclusivity periods beyond patent protection in Mexico?
Yes. Data exclusivity is generally five years for new chemical entities, offering market exclusivity independent of patent rights.
5. Does Mexico recognize pharmaceutical patent extensions?
Extensions are limited; patent term adjustments are rare. Most protection aligns with the standard 20-year term.
References
[1] Mexican Institute of Industrial Property (IMPI). (2022). Annual report on patent applications.
[2] World Intellectual Property Organization (WIPO). (2021). Patent cooperation treaty statistics.
[3] World Trade Organization. (1994). TRIPS Agreement.
[4] Barros, J., & Ramos, F. (2019). “Pharmaceutical patent landscape in Latin America.” Journal of Intellectual Property Law.
